Clinical dissection of multicentric Castleman disease

被引：37

作者：

Shin, Dong-Yeop ^{[1
]}

Jeon, Yoon Kyung ^{[2
]}

Hong, Yong-Sang ^{[3
]}

Kim, Tae Min ^{[1
,4
]}

Lee, Se-Hoon ^{[1
,4
]}

Kim, Dong-Wan ^{[1
,4
]}

Kim, Inho ^{[1
,4
]}

Yoon, Sung-Soo ^{[1
,4
]}

Heo, Dae Seog ^{[1
,4
]}

Park, Seonyang ^{[1
,4
]}

Kim, Byoung Kook ^{[1
,4
]}

机构：

[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 151, South Korea

[2] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul Natl Univ Hosp, Seoul 151, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Oncol, Seoul, South Korea

[4] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea

来源：

LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 08期

关键词：

Castleman disease; age; splenomegaly; prognosis; Kaposi sarcoma-associated herpes virus; KAPOSIS-SARCOMA; DNA-SEQUENCES; IL-6; POPULATION; MANAGEMENT; LYMPHOMA; SURVIVAL;

D O I：

10.3109/10428194.2011.574759

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study investigated the prognostic factors of Castleman disease (CD) and focused specifically on multicentric CD (MCD). Seventy patients with CD were studied. Forty-three patients (61.5%) had unicentric CD (UCD) and 27 patients (38.5%) had MCD. Thirty-six patients with UCD (83.7%) underwent surgical excision, and 25 patients with MCD (92.6%) received systemic treatment, including corticosteroids and combination chemotherapy. In the patients with MCD, age >60 years and the presence of splenomegaly were prognostic factors for progression-free survival (hazard ratio [HR] 9.01, 95% confidence interval [CI] 2.64-30.83 and HR 4.32, 95% CI 1.16-16.09) as well as overall survival (OS) in MCD (HR 8.7, 95% CI 2.83-26.84 and HR 2.9, 95% CI 0.95-9.02, respectively). Patients <= 60 years old without splenomegaly showed better OS than patients >60 years old or with splenomegaly (71.4% vs. 10.8% for 5-year OS). MCD might be dissected clinically by the simple parameters of age and presence of splenomegaly.

引用

页码：1517 / 1522

页数：6

共 30 条

[1] A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors [J].

Andersen, NS ;

Jensen, MK ;

Brown, PD ;

Geisler, CH .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) :401-408

[2]

[Anonymous], 2004, HDB DOCUMENTATION IN, P1

[3] Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 [J].

Aoki, Y ;

Jaffe, ES ;

Chang, Y ;

Jones, K ;

Teruya-Feldstein, J ;

Moore, PS ;

Tosato, G .

BLOOD, 1999, 93 (12) :4034-4043

[4]

Arya LS, 2004, J PEDIAT HEMATOL ONC, V26, P807

[5]

Bowne WB, 1999, CANCER, V85, P706, DOI 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO

[6]

2-7

[7] Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients [J].

Brenner, Hermann ;

Gondos, Adam ;

Pulte, Dianne .

BLOOD, 2008, 111 (06) :2977-2983

[8] The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care [J].

Casper, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :3-17

[9]

CASTLEMAN B, 1956, CANCER-AM CANCER SOC, V9, P822, DOI 10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO

[10]

2-4

← 1 2 3 →